BioStock

Copenhagen-based Evaxion Biotech runs several projects based on its proprietary AI drug discovery platform. The main candidate EVX-01 is developed as a combination therapy with checkpoint inhibitors. A phase IIb trial is planned to start this winter, in which EVX-01 will be combined with blockbuster drug Keytruda after a recent collaboration agreement between Evaxion and Merck & Co. subsidiary MSD. ... https://www.biostock.se//evaxion-biotech-to-test-evx-01-i/

Evaxion Biotech ska utvärdera EVX-01 tillsammans med Merck & Co. #BioStockSwe #LifeScience #EvaxionBiotech https://www.biostock.se//evaxion-biotech-ska-utvardera-ev/

Stärkande kvartal för Sprint Bioscience #BioStockSwe #LifeScience @SprintBio https://www.biostock.se//starkande-kvartal-for-sprint-bio/

Nyhetssvepet torsdag 28 oktober #BioStockSwe #LifeSciences https://www.biostock.se///nyhetssvepet-torsdag-28-oktober/

Invent Medic satsar med ny strategi och emission #BioStockSwe #LifeScience #InventMedic https://www.biostock.se//invent-medic-satsar-med-ny-strat/